

Date: October 24, 2024

To,

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G
Bandra Kurla Complex
Bandra East
Mumbai 400 051
Maharashtra, India

The General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001
Maharashtra, India

Symbol: EPIGRAL

Scrip Code: 543332

Dear Sir/Madam,

Re: Qualified institutions placement (“QIP” or “Issue”) of equity shares of face value of ₹10 each (the “Equity Shares”) by Epigral Limited (formerly known as Meghmani Finechem Limited) (the “Company”) under the provisions of Chapter VI of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the “SEBI ICDR Regulations”), and Sections 42 and 62 of the Companies Act, 2013 and the rules made thereunder, each as amended (the “Issue”)

Sub: Outcome of the meeting of the Fund Raising Committee

Further to our letter dated October 21, 2024, intimating you about the meeting of the Fund Raising Committee held on October 21, 2024 in respect of the QIP, we wish to inform you that in respect of the Issue, the Fund Raising Committee of the Company has, at its meeting today, i.e. October 24, 2024, *inter alia*, passed the following resolutions:

- (i) approved and declared the closure of Issue today, i.e. October 24, 2024 pursuant to the receipt of application forms for an aggregate of 15,91,180 fully paid-up Equity Shares of the Company and the funds in the escrow account from eligible qualified institutional buyers in accordance with the terms of the Issue;
- (ii) determined and approved, the allocation of 15,91,180 Equity Shares to be allotted to eligible QIBs at a price of ₹ 2093.13 per Equity Share, including a premium of ₹ 2083.13 per Equity Share, which takes into account a discount of ₹ 110.16 per Equity Share on the floor price amounting to ₹ 2203.29 per Equity Share (5% of the floor price), as permitted in terms of Regulation 176(1) of Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended;
- (iii) approved and finalized the confirmation of allocation note (“CAN”) to be sent to eligible qualified institutional buyers, intimating them of allocation of Equity Shares pursuant to the Issue;
- (iv) approved and adopted the placement document dated October 24, 2024 in connection with the Issue; and



Epigral Limited

(formerly known as **Meghmani Finechem Limited**)
Epigral Tower, Behind Safal Profitaire, Corporate Road
Prahladnagar, Ahmedabad 380015, Gujarat, India.

T +91 79 2970 9600
E info@epigral.com
W epigral.com

In this relation we are filing the placement document dated October 24, 2024 with your office. A copy of the same is also being made available on the website of our Company at www.epigral.com.

The Fund Raising Committee meeting commenced at 10:30 p.m. and the meeting was concluded at 10:45 p.m.

The Issue was opened on October 21, 2024 and the same was intimated to you pursuant to our letter dated October 21, 2024.

We request you to take the above on record, and the same be treated as compliance under the applicable regulations of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Thanking you,

Yours faithfully
For Epigral Limited
(formerly known as Meghmani Finechem Limited)

Gaurang Trivedi
Company Secretary and Compliance Officer
Membership No. A22307

Place: Ahmedabad

